Lorinda Chung

Publications

• Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. Chung L, Chen H, Khanna D, Steen VD. Arthritis Care Res (Hoboken). 2013; 65 (3): 454-63
• Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Yaqub A, Chung L. Curr Rheumatol Rep. 2013; 15 (1): 302
• Localized cutaneous fibrosing disorders. Yaqub A, Chung L, Rieger KE, Fiorentino DF. Rheum Dis Clin North Am. 2013; 39 (2): 347-64
• Management of the hand in systemic sclerosis. Fox P, Chung L, Chang J. J Hand Surg Am. 2013; 38 (5): 1012-6
• Clinical trial design in scleroderma: where are we and where do we go next? Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clin Exp Rheumatol. 2012 Mar-Apr; 30 (2 Suppl 71): S97-102
• Clinical presentation and evaluation of dermatomyositis. Marvi U, Chung L, Fiorentino DF. Indian J Dermatol. 2012; 57 (5): 375-81
• An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E, Rosen G, Chung L. J Rheumatol. 2011; 38 (4): 693-701
• Colonic ulceration as an unusual manifestation of vasculopathy in systemic sclerosis. Kao L, Myer P, Nguyen L, Zamanian RT, Chung L. Rheumatology (Oxford). 2011; 50 (3): 626-8
• Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. Arefiev K, Fiorentino DF, Chung L. Int J Rheumatol. 2011: 2011 201787
• Hyperuricemia and the risk for subclinical coronary atherosclerosis--data from a prospective observational cohort study. Krishnan E, Pandya BJ, Chung L, Dabbous O. Arthritis Res Ther. 2011; 13 (2): R66
• Pathogenesis of dermatomyositis: role of cytokines and interferon. Kao L, Chung L, Fiorentino DF. Curr Rheumatol Rep. 2011; 13 (3): 225-32
• The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. J Am Acad Dermatol. 2011; 65 (1): 25-34
• Tyrosine kinases in inflammatory dermatologic disease. Paniagua RT, Fiorentino DF, Chung L, Robinson WH. J Am Acad Dermatol. 2011; 65 (2): 389-403
• A 39-year-old woman with lupus, myositis, and a recalcitrant vasculopathy. Sokolove J, Copland A, Shirvani S, Brown J, Posley K, Chung L. Arthritis Care Res (Hoboken). 2010; 62 (9): 1351-6
• Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Chest. 2010; 138 (6): 1383-94
• Digital ischemic loss in systemic sclerosis. Marvi U, Chung L. Int J Rheumatol. 2010 2010
• Vascular disease in systemic sclerosis. Chung L, Distler O, Hummers L, Krishnan E, Steen V. Int J Rheumatol. 2010: 2010 714172
• Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients. Schmajuk G, Bush TM, Burkham J, Krishnan E, Chung L. Clin Exp Rheumatol. 2009 May-Jun; 27 (3 Suppl 54): 22-5
• MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. Arthritis Rheum. 2009; 60 (3): 870-7
• Molecular framework for response to imatinib mesylate in systemic sclerosis. Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH. Arthritis Rheum. 2009; 60 (2): 584-91
• Malignancy in the setting of the anti-synthetase syndrome. Rozelle A, Trieu S, Chung L. J Clin Rheumatol. 2008; 14 (5): 285-8
• Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Chakravarty EF, Khanna D, Chung L. Obstet Gynecol. 2008; 111 (4): 927-34
• A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, Genovese MC. J Rheumatol. 2007; 34 (6): 1323-7
• A pilot trial of rituximab in the treatment of patients with dermatomyositis. Chung L, Genovese MC, Fiorentino DF. Arch Dermatol. 2007; 143 (6): 763-7
• Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Chung L, Krishnan E, Chakravarty EF. Rheumatology (Oxford). 2007; 46 (12): 1808-13
• Therapeutic options for digital ulcers in patients with systemic sclerosis. Chung L, J Dtsch Dermatol Ges. 2007; 5 (6): 460-5
• Systemic and localized scleroderma. Chung L, Lin J, Furst DE, Fiorentino D. Clin Dermatol. 2006 Sep-Oct; 24 (5): 374-92
• A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. Chung L, Fiorentino D. J Am Acad Dermatol. 2006; 54 (5): 880-2
• Digital ulcers in patients with systemic sclerosis. Chung L, Fiorentino D. Autoimmun Rev. 2006; 5 (2): 125-8
• Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Chung L, Flyckt RL, Colón I, Shah AA, Druzin M, Chakravarty EF. Lupus. 2006; 15 (9): 595-9
• Successful use of rituximab for cutaneous vasculitis. Chung L, Funke AA, Chakravarty EF, Callen JP, Fiorentino DF. Arch Dermatol. 2006; 142 (11): 1407-10
• Bleeding complications in patients on celecoxib and warfarin. Chung L, Chakravarty EF, Kearns P, Wang C, Bush TM. J Clin Pharm Ther. 2005; 30 (5): 471-7
• Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus. Chung L, Berry GJ, Chakravarty EF. Lupus. 2005; 14 (2): 166-9
• Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Chung L, Utz PJ. Curr Rheumatol Rep. 2004; 6 (2): 156-63